Fig. 1 · Structure

Documents & Downloads

RLX

Cat. No. A25782 CAS 4425-23-4

PI3K/Akt/FoxO3a Inhibitor

RLX (PD 139530) is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, exhibiting significant therapeutic potential in colon cancer models. This compound can effectively modulate the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy. Additionally, RLX improves the retention time of therapeutic agents in tumors through advanced nanoparticle delivery systems and can be combined with various treatment modalities, such as chemotherapy and radiotherapy, to synergistically enhance cancer treatment outcomes.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 4425-23-4
Applications PI3K/Akt/FoxO3a Inhibitor
Formula C13H14N2O
Molecular Weight 214.26
Synonyms PD 139530
SMILES
O=C1N2C(CCCCC2)=NC3=C1C=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Added to your cart

View Cart Checkout
Loading...